Abstract Library

#4345 Real-life results of the treatment with lutetium in advanced neuroendocrine tumours

Introduction: Therapy using lutetium-177 dotatate (177LU) was approved in Europe in 2017 for the treatment of advanced neuroendocrine tumours (NETs). Since then, it has become part of the strategies for treating NETs, making it now possible to evaluate real-life results.

Conference:

Presenting Author: Campos Ramírez S

Authors: Campos Ramírez S, Andrés A, Gómez Mugarza P, Blanco Abad C, Monreal Cepero M,

Keywords: Neuroendocrine tumour, Lutetium, Efficacy, Toxicity, Real-Word Evidence,

#4250 Lutetium-177 Dotatate Peptide Receptor Radionuclide Therapy in metastatic pheochromocytoma and paraganglioma: Experience in our center

Introduction: -

Conference:

Presenting Author: Negre M

Authors: Negre M, Guardeño R, Biarnés J, Recasens M, Rubió A,

Keywords: PRRT, 177Lu-Dotatate, Metastastatic Paraganglioma, Metastatic Pheocromocytoma,

#3823 Added value of post 177Lu Dotatate and Ga PET/CT imaging in prediction and evaluation of treatment response for GEP NETs

Introduction: Theragnostic approach using 68Ga Dota-peptides (PET) for diagnosis and Lutetium-177 Dotatate (Lutate) for therapy is approved in gastroenteropancreatic neuroendocrine tumors (GEP-NET). The 24-hour post-Lutate treatment imaging (Lutate post tp) evaluates the radiotracer distribution.

Conference:

Presenting Author: Abenavoli E

Authors: Abenavoli E, Linguanti F, Briganti V, Antonuzzo L, Mungai F,

Keywords: Lutetium-177 Dotatate, 68Ga-Dota peptide, evaluation response, prediction response, imaging parameter,

#3687 Lutetium-177 DOTATATE PRRT versus PRRT plus chemotherapy in metastatic well differentiated FDG-avid GEP-NETs – Results from a prospective cohort

Introduction: Combination therapy with PRRT and Capecitabine-Temozolomide (CAPE-TMZ) has benefited patients with FDG avid well-differentiated GEP-NETs.

Conference:

Presenting Author:

Authors: Puranik A, Rangarajan V, Shrikhande S, Ramaswamy A, Ostwal V,

Keywords: PRRT, capecitabine, temozolomide, FDG PET, DOTA PET,

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,